What is Scienture Holdings, Inc. (SCNX)?

Scienture Holdings, Inc. (SCNX) is a stock in the Healthcare sector, Medical - Pharmaceuticals industry. View full analysis on Stocks360.

What is the current price of SCNX?

The current price of SCNX is $3.49. Prices are updated in real time on Stocks360.

What is SCNX's price-to-earnings (PE) ratio?

SCNX's trailing twelve-month PE ratio is -0.08, based on current price and earnings per share data available on Stocks360.

What is SCNX's market capitalization?

SCNX's market capitalization is $5,732,552.00, placing it in the small-cap tier.

Scienture Holdings, Inc. (SCNX)

Stock analysis · NASDAQ · Healthcare · Medical - Pharmaceuticals

$3.49

Market Cap

$5.73M

PE (TTM)

-0.08

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

4.08

Day Range

$3.31 – $3.67

52-wk Range

$2.64 – $27.75

Avg Volume

N/A

Volume

58.34K

Scienture Holdings, Inc. (SCNX) is a publicly traded company in the Healthcare sector. Latest price: $3.49. Market cap $5.73M. Trailing PE -0.08. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 6 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-30 · $19.19 2026-10-29 · $3.49 (-81.81%)

Earnings

Most Recent

Aug 13, 2026

EPS $-1.75 vs est. $-2.25

Beat by $0.50

Next Earnings

Nov 11, 2026

EPS estimate $-1.57

Proprietary Signals

Signal snapshot temporarily unavailable.

About Scienture Holdings, Inc.

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.08×
P/S (TTM)	6.98×
P/B	0.09×
P/FCF (TTM)	-0.40×
EV / EBITDA	-0.23×
EV / Sales	10.03×
Earnings Yield	-686.25%
Free Cash Flow Yield	-251.90%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$8.23M
Revenue (TTM)	$821.32K
Net Income (TTM)	-$39.34M
Free Cash Flow (TTM)	-$11.53M
Net Debt	$2.50M
Working Capital	$6.18M
Gross Margin	30.73%
Operating Margin	-1671.08%
Net Margin	-4620.92%
Return on Equity	-53.51%
Return on Invested Capital	-15.19%